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ABSTRACT 
 An accurate, simple and precise RP-HPLC Bio-Analytical method has been 
developed and validated for the estimation of Saxagliptin from human plasma.. The method 
was developed using enable C18 column and potassium di hydrogen ortho phosphate 
buffer with 0.01 M 1-heptane sulphonic acid used as aqueous phase (pH adjusted to 3.5 
with orthophoshoric acid) and organic phase as acetonitrile (72:28). The flow rate was 
maintained at 1.0 ml/min and detected at a wavelength of 223 nm using PDA detector. 
Separation of Saxagliptin was achieved with a C18 column (250mmx4.6mmx50 µm )  and 
the retention time  was found to be 4.4  min. The method was linear over the range of 0.5 
to  2.5µg/ml .  The good percentage recovery clearly confirmed the reproducibility and 
accuracy of the developed method. The %RSD value for precision was also within the 
acceptable limit. The robustness studies were performed by changing the pH, wavelength 
and flow rate by chemometric method. Satisfactory data was obtained for all the method 
validation parameters tested. The results of the study showed that the developed RP-HPLC 
method was found to be simple, rapid, precise, accurate, robust and stability indicating 
which can be used for routine analysis of Saxagliptin from plasma and biological matrix. 
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1. INTRODUCTION1-7 
Analytical Techniques 
An analytical chemistry helps to find the characteristics of drug components and 
related products by checking its quality and quantity measurements. With such those 
uses it is still taking important place in chemistry. 
Common Analytical Techniques for Analysis ; 
  Chemical methods 
  a) Titrimetric or volumetric methods 
  b) Gravimetric methods 
  c) Gasometrical analysis  
 Electrical methods 
  a) Potentiometry  
  b) Conductometry  
  c) Polarography  
  d) Voltametry  
  e) Amperometry  
 Instrumental methods 
  Spectroscopic methods 
  Chromatographic techniques: 
  X-ray methods:  
  Radioactivity:  
  Optical methods: 
  Thermal methods: 
 Biological and microbiological methods 
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY  
In the modern pharmaceutical industry, HPLC is a major analytical tool applied 
at all stages of drug discovery, development and production . 
Most of the drugs in multicomponent dosage forms can be analyzed by HPLC 
method because of the several advantages like good separation, rapidity, specificity, 
accuracy, precision and ease of automation in this method. HPLC method eliminates 
tedious extraction and isolation procedures. Some of the advantages are:  
 
PRINCIPLE 
The HPLC separation is performed by injecting the sample dissolved in solvent 
into a stream of solvent being pumped into a column. Here the principle is a liquid-solid 
separation. It occurs when mixture of compounds dissolved in a solvent can either stay in 
the solvent or adhere to the packing material in the column.  
 
Types of liquid chromatography  
a. Partition Chromatography 
b. Adsorption Chromatography 
c. Ion exchange Chromatography 
d. Size exclusion or gel permeation Chromatography 
 
Depending on the relative polarity of the two phases: 
 Normal-Phase Chromatography  
 Reversed-Phase Chromatography  
 
Nature of the stationary phase and the separation process, 
        Three modes can be specified: 
 Adsorption Chromatography:  
  Ion-Exchange Chromatography: 
  Size Exclusion Chromatography: 
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Instrumentation of HPLC: 
The features of modern HPLC are illustrated in the block diagram comprise of 
components. 
                                      
1. Pumping system: 
Features of pumping system 
High pressures up to 6000 psi, Constant & reproducible flow, Pulse free output, Flow 
rate (0.1-10mL), Adaptable to gradient flow, Corrosion resistant components, Easy to 
dismantle & repair and Low maintenance cost.  
 
2. An injector: 
 
3. Chromatographic column: 
Types of column: 
 Analytical Column: 
 Preparative Column: 
 
4. Detector: 
 There are six main detectors used for HPLC: Refractive index (RI),     Ultraviolet 
(UV), Fluorescence (FL), Conductivity (CD), Electrochemical (EC) and Mass 
Spectrometric (MS). 
 
5.Data system 
 
Quantification Methods in HPLC 
         The four primary techniques for quantification are  
 Normalized peak area method 
 External Standard method 
 Internal Standard method 
 Method of Standard addition 
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System Suitability 
 System suitability testing is an integral part of analytical procedures. 
 System suitability test parameters to be established for a particular procedure depend 
on the type of procedure being validated. 
 
i) Resolution (Rs): 
The resolution, Rs, of two neighboring peaks is defined by the ratio of the 
distance between the two peak maxima. For baseline separation, the ideal value of Rs is 
1.5. It is calculated by using the formula, 
                                                     Rs   = 
 21
12
5.0 WW
RtRt


 
Where, Rt1 and Rt2 are the retention times of components 1 and 2 and  
             W1 and W2 are peak widths of components 1 and 2. 
 
ii) Capacity factor (k’): 
Capacity factor k’, is defined as the ratio of the number of molecules of solute in 
the stationary phase to the number of molecules of the same in the mobile phase. 
Capacity factor can be determined by using the formula, 
                                 K’   = S
V
VV


0
01
 
Where, V1 = retention volume at the apex of the peak (solute)  
              V0 = void volume of the system. 
 Typically an increase in percentage of the organic phase by 10 % by volume will 
decrease k’ of the bands by a factor of 2-3.  
iii) Selectivity (): 
The selectivity (or separation factor),  is a measure of relative retention of two 
components in a mixture. The ideal value of selectivity is 2. It can be calculated by using 
the formula,                                        
                                      α   = 
01
02
VV
VV


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     Where, V0 is the void volume of the column and V2 and V1 are the retention    
volumes of the second and the first peak respectively. 
iv) Column efficiency (N): 
Efficiency, N, of a column is measured by the number of theoretical plates per 
meter. It is a measure of band spreading of a peak.  Columns with N ranging from 2000 - 
100,000 plates/meter are ideal for a good system. Efficiency is calculated by using the 
formula, 
   N   =   
2
2
16
W
Rt
, 
Where, Rt is the retention time and W is the peak width. 
 
v) Peak asymmetry factor (As): 
Peak asymmetry factor, as, can be used as a criterion of column performance. 
The peak half width, b, of a peak at 10 % of the peak height, divided by the 
corresponding front half width, a, gives the asymmetry factor. 
   As =
a
b
   
For a well packed column, an asymmetry factor of 0.9 to 1.1 should be 
achievable. 
 
vi)Theoretical plate number / Efficiency (N): 
A measure of peak band spreading determined by various methods, some of 
which are sensitive to peak asymmetry.  
4-sigma / tangential 
 
 N = 16 (tR / W) 2 = L / H 
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Half height 
 N = 5.54(tR/ W) 2 = L / H 
Where,    tR - Retention time for the sample peak. 
               W - Peak width. 
               N is fairly constant for each peak on a chromatogram with a fixed set of 
operating conditions. H (height), or HETP (height equivalent of a theoretical plate), 
measures the column efficiency per unit length (L) of the column. Parameters which can 
affect N or H include. 
Peak position, particle size in column, flow-rate of mobile phase, column temperature, 
viscosity of mobile phase, and molecular weight of the analyte. 
The theoretical plate number depends on elution time but in general should be > 2000. 
vii) Tailing factor (T): 
It is the measure of the symmetry of a peak. 
 T = W0.05 / 2f 
Where,      W0.05 - Peak width at 5% height  
                  F - Distance from peak front to apex point at 5% height. 
Limits -T</= 2. 
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Analytical method development and validation
 [8-18] 
 Analytical method development and validation play an important role in the 
discovery, development, and manufacture of pharmaceutical formulations. 
  Method development 
 
  Validation of chromatographic methods   
 
Basic criteria for new method development of drug analysis 
 The drug or drug combination may not be official in any pharmacopoeias. 
 A proper analytical procedure for the drug may not be available in the literature due 
to patent regulations. 
 Analytical methods may not be available for the drug in the form of a formulation 
due to the interference caused by the formulation excipients.  
 Analytical methods for the quantification of the drug in biological fluids may not be 
available. 
Validation of chromatographic methods   
 A detailed discussion on the parameters to be validated:  Specificity: peak purity 
determination * Linearity * Range * Accuracy * Precision * Detection Limit * 
Quantification Limit * Robustness 
 
Accuracy/recovery studies: 
The accuracy of an analytical method is the closeness of test results obtained by 
that method to the true value. 
                             Cm × 100                             
      Ct 
 The % recovery was calculated using the formula, 
                                       100
)(
covRe%
bX
aba
ery

  
Where, 
 a – Amount of drug present in sample 
 b – Amount of drug added to the sample 
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Acceptance Criteria: 
 For an assay method, mean recovery will be 100%± 2% at each concentration 
over the range of 80-120% of the target concentration. 
 For an impurity method, mean recovery will be 0.1% absolute of the theoretical 
concentration or 10% relative, whichever is greater for impurities in the range 
of 0.1-2.5 % (V/W). 
 
Precision: 
Precision is the measurement of the degree of repeatability of an analytical method under 
normal operation, and is normally expressed as the % relative standard deviation for a 
statistically significant number of samples.  
Acceptance Criteria: 
 Percentage Relative  deviation (%RSD)  NMT 1 % (Instrument precision) 
 (%RSD)  NMT -2% (Intra- assay precision) 
Precision may be per-formed at three different levels: 
Repeatability, 
Intermediate Precision And 
Reproducibility. 
Repeatability: 
Repeatability (intra-day assay precision) is the results of the method operating 
over a short time interval under the same conditions (intra-assay precision).  
Intermediate Precision: 
Intermediate precision (inter-day variation) is the results from within lab 
variations, due to random events, such as different days, analysts, equipment, etc.  
Reproducibility: 
Reproducibility is determined by testing homogeneous samples in multiple 
laboratories, often as part of inter-laboratory crossover studies.  
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Limit of Detection and Quantitation: 
The Limit of Detection (LOD) and Limit of Quantitation (LOQ) tests for the 
procedure are performed on samples containing very low concentrations of analyte. 
The detection limit (DL) may be expressed as: 
                        LOD = 3.3 σ / S 
The low limit of quantification may be expressed as                        
                        LOQ = 10 σ / S 
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Bio-Analytical method development 
[19-24] 
 The procedures that demonstrate that a particular method used for quantitative 
measurement of analytes in a given biological matrix, such as blood, plasma, serum, or 
urine, is reliable and reproducible for the intended use. 
 Pharmaceutical products prepared with one drug or more than that ,but every 
drug formulations used depends on the bioavailability of that particulars in human or 
animal body. So to check the bio availability and its half life analyst having responsible 
to analyse the drugs in human and animal  plasma. 
   This is also applies to bioanalytical methods used for non-human 
pharmacology/toxicology studies and preclinical studies.  
Following instrumentation methods can be used for bio-analytical method development, 
1.Gas Chromatography(GC) 
2.High-pressure Liquid chromatography (LC) 
3.Combined GC and LC mass spectrometric (MS) 
4. LC-MS 
5.LC-MS-MS 
6.GC-MS and 
7. GC-MS-MS 
 The process by which a specific bioanalytical method is developed, validated, 
and used in routine sample analysis can be divided into 
 1. Reference Standard preparation 
 2. Bioanalytical method development and establishment of assay  procedure 
 3. Application of validated bioanalytical method to routine drug analysis  and 
acceptance criteria for the analytical run and/or batch. 
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1. Reference Standard: 
 Analysis of drugs and their metabolites in a biological matrix is carried out using 
samples spiked with calibration (reference) standards and using quality control (QC) 
samples.  If possible, the reference standard should be identical to the analyte. When this 
is not possible, an established chemical form (free base or acid, salt or ester) of known 
purity can be used. 
2. Bioanalytical Method Development: 
 The method development and establishment phase defines the chemical assay. 
Typical method development and establishment for a bioanalytical method include 
determination of (1) selectivity, (2) accuracy, precision, recovery, (3) calibration curve, 
and (4) stability of analyte in spiked samples. 
A. Selectivity 
 It is the ability of an analytical method to differentiate and quantify the analyte in 
the presence of other components in the sample mixture. If the method is intended to 
quantify more than one analyte, each analyte should be tested to ensure that there is no 
interference. 
B. Accuracy, Precision, and Recovery  
Accuracy – 
 The accuracy of an analytical method describes the closeness of mean test results 
obtained by the method to the true value (concentration) of the analyte. The mean value 
should be within 15% of the actual value except at LLOQ, where it should not deviate by 
more than 20%.  
Precision - 
 The precision of an analytical method describes the closeness of individual 
measures of an analyte when the procedure is applied repeatedly to multiple aliquots of a 
single homogeneous volume of biological matrix. 
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subdivided into 
1.Within-run, intra-batch precision or repeatability: This assesses precision during a 
single analytical run, 
2.Between-run, inter-batch precision or repeatability: This measures precision with time, 
and may involve different analysts, equipment, reagents, and laboratories. 
Recovery  
 The recovery of an analyte in an assay is the detector response obtained from an 
amount of the analyte added to and extracted from the biological matrix, compared to the 
detector response obtained for the true concentration of the pure authentic standard. . 
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2. LITERATURE REVIEW  
  
1. P. Srinivasa Rao et al25 studied Stability indicating isocratic reverse phase HPLC 
method for the estimation of Saxagliptin in bulk drugs and in its formulation 
Separation was achieved with a Eclipse XDB C18, ( 150 mm × 4.6 mm X 5 μm) 
Column and Potassium di-hydrogen orthophosphate buffer with TEA (pH adjusted 
to 3.4 with OPA): Acetonitrile (80:20) v/v as eluent at a flow rate of 1.0 mL/min. 
UV detection was carried out at 213 nm. The retention time of Saxagliptin was 
found to be 3.8 minutes. 
 
2. Bhagavanji26 reported that, a study on  development and validation of stability 
indicating liquid chromatographic method for the simultaneous estimation of 
Metformin and Saxagliptin in combined dosage form by thermo Hypersil BDS C8 
(250mmX4.6mmX5μ) column  was used  with mobile phase containing water pH 
3.0 adjusted with ortho phosphoric acid: methanol in the ratio of (70: 30, v/v). The 
flow rate was 1.0 mL/min, column temparature was 30°C and effluents were 
monitored at 241 nm. The retention times of Metformin and Saxagliptin were 
4.7min and 6.8 min, respectively.  
 
 
3. Karkhanis Vaishali  et al27 has reported and study on development and validation of 
a liquid chromatographic method for estimation of Saxagliptin in tablet dosage form 
achieved by Hypersil C18 column (250mm X 4.6mm, 5μm) in isocratic mode, the 
mobile phase comprises of Acetonitrile: Buffer in ratio of 30:70 v/v, buffer was 
0.02M Potassium Di-hydrogen Phosphate (pH 4.5 adjusted with OPA). The flow 
rate of mobile phase was 1.0ml/min and detection UV wavelength 220nm. The 
retention time of saxagliptin was 3.487 min. 
 
4. Sarat et al28 has been reported and study on reverse phase HPLC method for 
simultaneous estimation of Saxagliptin and Pioglitazone in tablets. Chromatographic 
seperation achieved isocratically on Inerstil C18 column (150mmX 4.6 mmX5μm) 
using mobile phase of Acetonitrile and Phosphate buffer pH 7.0 (60:40 v/v)at a flow 
rate of 0.8 ml/min with UV wave length of 260 nm. Aceclofenac was used as 
internal standard. The RT of Saxagliptin, pioglitazone and aceclofenac was 2.48, 
4.45 and 6.34 min respectively.  
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3. DRUG PROFILE [25-28] 
 
 Drug Name  :       Saxagliptin 
 Molecular formulae :       C18H25N3O2   
 Molecular weight     :       315.41 g/mol  
 
 
   Chemical structure  
 
 
 Chemical name  :  2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl) 
                                                  acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile 
 Colour and nature : White to yellow or light brown crystalline powder. 
 Solubility  :           Sparingly soluble in water ,slightly soluble in ethyl acetate          
     and soluble in methanol, ethanol ,isopropyl alcohol,  
     acetonitrile ,acetone and PEG-400. 
 Category  : Oral hypoglycemic agent (anti-diabetic drug) (DPP-4       
     inhibitor.)  
 Dosage Form  : Available as 2.5 mg and 5 mg tablet. 
 Index of Refraction : 1.6. 
 Boiling Point  :  548.7±35.0 °C at 760 mmHg. 
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 Molar Refractivity : 84.2±0.4 cm3 . 
 Enthalpy of  
Vaporization  : 95.2±6.0 kJ/mol. 
 Class   : Carboxylic Acids and Derivatives. 
 Subclass  : Amino Acids, Peptides, and Analogues. 
 Direct Parent  : Alpha Amino Acid Amides. 
 Half life  : 2.5 hours. 
 pKa (strongest acidic) : 14.74. 
 pKa (strongest basic) : 7.9. 
 Toxicity  : Upper respiratory tract infection, urinary tract infection,  
     and headache. 
 Route of elimination : Eliminated by both renal and hepatic pathways. 
 
 
Pharmacology: 
 
Saxagliptin is used along with  the diet and activities to lower blood sugar levels in 
patients with type 2 diabetes Saxagliptin is in a class of oral diabetic drugs called  dipeptidyl 
peptidase-4 (DPP-4) inhibitors. Saxagliptin is not used to treat type 1 diabetes or diabetic 
ketoacidosis. It works by increasing the quantity of insulin produced by the body after meals 
when blood sugar is high. 
 
 
 
 
 
 
                                         
Aim & Objectives 
 
Dept. of Pharmaceutical Analysis Page 16 
 
4. AIM AND OBJECTIVES OF THE WORK  
 Importance of analytical chemistry is to gain information about the qualitative 
and quantitative composition of substance and chemical species, that is, to find out what 
a substance is composed of and exactly how much it is present.  
Drug analysis plays an important role in the development of drugs, their 
manufacture and therapeutic use. Pharmaceutical industries rely up on quantitative 
chemical analysis to ensure that the raw material used and the final product obtained 
meets the required specification. 
 
Saxagliptin is part of a class of diabetes medications called dipeptidyl peptidase-
4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down incretin hormones. As 
a DPP-4 inhibitor, Saxagliptin slows down the breakdown of incretin hormones, 
increasing the level of these hormones in the body.  
  
The literature revealed that only four methods [29-32] have been reported for 
estimation of saxagliptin in single or combined dosage forms by RP-HPLC. 
  
Previously described methods for saxagliptin were technically lack of sensitivity 
and using high proportion of organic mobile phases. However  Bio anlytical methods 
were not been reported for saxagliptin  estimation in human plasma. 
  
The prime objective of this work is to develop rapid, selective, sensitive and 
economical Bio analytical method for saxagliptin in human plasma with an internal 
standard by RP-HPLC method. 
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5. PLAN OF WORK  
 The work plan was to develop RP-HPLC method for Bio analytical estimation of 
Saxagliptin. 
The plan of work was divided into two phases. 
Phase I: 
Optimization of chromatographic conditions  
 Selection of wavelength  
 Selection of initial separation conditions   
 Selection of mobile phase (pH, peak modifier, solvent strength, ratio and flow 
rate) 
 Nature of the stationary phase 
 Selection of separation method and agent 
Phase II: 
 
Validation of the method 
 
The developed method were proposed to be validated using the various validation 
parameters such as,  
Accuracy 
Precision 
             Interday 
             Intraday 
             Repeatability 
Linearity  
Limit of detection (LOD)  
 Limit of quantification (LOQ) 
 Robustness   
 Ruggedness    
System suitability. 
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6. METHODOLOGY 
HPLC METHOD DEVELOPMENT [29-33] 
MATERIALS AND INSTRUMENTS USED 
a) Drug samples: 
              Saxagliptin gift sample was procured from Madras pharmaceuticals, Chennai.  
b) Chemicals and Solvents used: 
 Water HPLC Grade 
 Acetonitrile HPLC grade 
 Methanol HPLC grade 
 Orthophosphoric acid AR grade 
 1-Heptane sulphonic acid 
 Tri ethyl amine 
c) Instruments used: 
 Shimadzu AY 220 Electronic Weighing Balance 
 Eutech pH meter  
 Sonica Ultrasonicator.  
 Millipore membrane filter  
 Shimadzu prominence HPLC 
  Pump – Prominence LC-20AT 
 Column -Enable C18 (2) 100A, (250 X 4.6m.m x i.d, 5µ) 
 Injector -   Rheodyne 7725i with 20 μl loop 
 Detector - Photo Diode Array Detector  
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METHOD DEVELOPMENT AND OPTIMIZATION OF CHROMATOGRAPHIC 
CONDITION FOR THE ESTIMATION OF SAXAGLIPTIN 
The present work is the development of the RP-HPLC method development of 
saxagliptin. 
a) Selection of Wavelength 
The wavelength for the analysis of saxagliptin was selected by injecting several 
times of standard of 10 µg/ml of saxagliptin, for an optimum detection of the drug. since 
it have shown maximum absorbance at 223 nm, finally  which was selected as an 
optimum wave length for the estimation.   
b) Selection of method for separation 
Proper selection of the method depends upon the nature of the sample 
(ionic/ionisable/neutral molecule), its molecular weight and solubility. The drug selected 
in the present study is polar in nature and hence the reverse phase HPLC was selected for 
the initial separations because of its simplicity and suitability. 
c) Initial chromatographic conditions adopted for the separation of Saxagliptin 
Chromatographic Conditions – 1  
 Stationary phase  :  Enable C18 column  
 Mobile phase    :  Solvent A – HPLC grade water   
     : Solvent B - Acetonitrile:Methanol(30:20)  
 Solvent ratio    : 50: 50 (A: B)  
 Detection Wavelength  : 223 nm  
 Flow rate    : 1.0 ml/min  
 Temperature                            : 25ºC  
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 5.3 min. The peaks observed was broad and asymmetric hence not selected 
further for method development. 
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Chromatographic Conditions – 2  
 Stationary phase  :  Enable C18 column  
 Mobile phase    :  Solvent A – HPLC grade water   
     : Solvent B - Acetonitrile: Methanol(30:20)  
 Solvent ratio    : 40: 60 (A: B)  
 Detection Wavelength  : 223 nm  
 Flow rate    : 1.0 ml/min  
 Temperature                            : 25ºC  
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 5.3 min. The peak observed was broad and asymmetric hence not selected further 
for method development. Hence no development from last method it would not be 
followed for further studies. 
 
Chromatographic Conditions – 3 
      Stationary phase  :  Enable C18 column  
 Mobile phase   :  Solvent A – HPLC grade water pH adjust to  4.0 
        (with orthophosphoric acid)  
     :  Solvent B - Acetonitrile:Methanol(30:20)
 Solvent ratio   : 50: 50 (A: B)  
 Detection Wavelength : 223 nm  
 Flow rate   : 1.0 ml/min  
 Temperature   : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 5.3 min. The peak observed was broad and asymmetric hence not selected further 
for method development. Hence no development from last method it would not be 
followed for further studies .Mostly the same result was observed same like 
chromatographic condition-2. 
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Chromatographic Conditions – 4 
      Stationary phase   : Enable C18 column  
 Mobile phase    : Solvent A - Water pH 3.5 with 0.5%TEA  
     : Solvent B - Acetonitrile:Methanol(30:20)
 Solvent ratio   : 50:50 (A: B)  
 Detection Wavelength  : 223 nm  
 Flow rate    : 1.0 ml/min  
 Temperature    : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 2.2 min. The peak observed was good but the RT of plasma will be in same RT 
of saxagliptin  hence not selected further for method development.  
 
Chromatographic Conditions – 5 
      Stationary phase   : Enable C18 column  
 Mobile phase    : Solvent A - Water pH 3.5 with 0.5%TEA  
     : Solvent B - Acetonitrile:Methanol(30:20)
 Solvent ratio   : 65: 35 (A: B)  
 Detection Wavelength  : 223 nm  
 Flow rate    : 1.0 ml/min  
 Temperature    : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 2.2 min. The peak observed was splitting and asymmetric hence not selected 
further for method development. Hence no development from last method it would not 
be followed for further studies.  
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Chromatographic Conditions – 6 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 4.0  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile:Methanol(30:20) 
 Solvent ratio             : 50: 50 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 2.02 min. The peak observed was sharp but 2.02 min RT hence not selected 
further for method development in plasma. 
 
Chromatographic Conditions – 7 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 4.0  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile:Methanol(30:20) 
 Solvent ratio             : 60: 40 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 1.09 min. The peak observed was good but RT in too short hence not selected 
further for method development.  
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Chromatographic Conditions – 8 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
     to 4.0  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 70: 30 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 3.2 min. The peak observed was good but because of the same RT problem not 
selected further for method development  
Chromatographic Conditions – 9 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 4.0 (with Orthophosphoric acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 80: 20 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 3.2 min. The peak observed was broad and asymmetric hence not selected further 
for method development.  
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Chromatographic Conditions – 10 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 4.0 (with Orthophosphoric acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 60: 40 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 3.02 min. The peak observed was sharp RT will come with plasma peak hence 
not selected further for method development  
Chromatographic Conditions – 11 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 4.0  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 65:35 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 3.04 min. The peak was sharp. Hence no development from last method it would 
not be followed for further studies.  
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Chromatographic Conditions – 12 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 4.0 (with Orthophosphoric acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 70:30 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 3.2 min. The peaks observed was broad and asymmetric hence not selected 
further for method development.  
 
Chromatographic Conditions – 13 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 5.0 (with Orthophosphoric acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 65:35 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 3.28 min. The peaks observed was sharp and no change in RT hence not selected 
further for method development.  
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Chromatographic Conditions – 14 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 3.0  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 65:35 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 2.89 min. The peaks observed was sharp and RT was before three min hence not 
selected further for method development.  
 
Chromatographic Conditions – 15 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 3.5  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 65:35 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 2.8  min. The peaks observed was sharp but no development in RT hence not 
selected further for method development.  
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Chromatographic Conditions – 16 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 3.5  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 70:30 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 3.2 min. The peaks observed was sharp but RT near to 3 min hence not selected 
further for method development.  
Chromatographic Conditions – 17 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 3.5  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 75:25 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 3.4 min. The peaks observed was sharp but RT not shifted after fourth min hence 
not selected further for method development.  
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Chromatographic Conditions – 18 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 3.5(with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 70:30 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at the retention 
time of 3.2 min. The peaks observed was sharp but RT not shifted after fourth min hence 
not selected further for method development.  
 
Chromatographic Conditions – 19 
 Stationary phase     : Enable C18 column  
 Mobile phase             : Solvent A –Phosphate buffer pH Adjusted                
       to 3.5  (with Orthophosphoric  acid)  
                        : Solvent B – Acetonitrile 
 Solvent ratio             : 73:27 (A: B)  
 Detection Wavelength            : 223 nm  
 Flow rate               : 1.0 ml/min  
 Temperature               : 25ºC  
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 3.4 min. The peaks observed was sharp but no change in RT hence not selected 
further for method development.  
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Chromatographic Conditions – 20 
        Stationary phase                : Enable C18 column  
Mobile phase                                :  Solvent A – 1-heptane sulphonic acid 
         Phosphate buffer pH adjusted  to 3.5(with 
 Orthophosphoric acid) 
                                                              : Solvent B – Acetonitrile   
           Solvent ratio                              :  70: 30 (A: B)  
           Detection Wavelength              :  223 nm  
           Flow rate                          :  1.0 ml/min  
          Temperature                             :   25ºC 
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 3.4 min. The peaks observed was sharp but  no change in RT hence not selected 
further for method development.  
 
Chromatographic Conditions – 21 
        Stationary phase                : Enable C18 column  
Mobile phase                                :  Solvent A – 1-heptane sulphonic acid 
         Phosphate buffer pH adjusted  to 3.5(with 
 Orthophosphoric acid) 
                                                              :  Solvent B – Acetonitrile   
           Solvent ratio                              :  73: 27 (A: B)  
           Detection Wavelength              :  223 nm  
           Flow rate                          :  1.0 ml/min  
          Temperature                             :   25ºC 
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 4.5 min. The peaks observed was sharp and RT also shifted  after fourth min 
hence this buffer has been  selected further for method development.  
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Chromatographic Conditions – 22 
          Stationary phase               : Enable C18 column  
Mobile phase                                : Solvent A – 1-heptane sulphonic acid 
        Phosphate buffer pH adjusted  to 3.5(with 
Orthophosphoric acid) 
                                                              : Solvent B – Acetonitrile   
           Solvent ratio                              :  75:25 (A: B)  
           Detection Wavelength              :  223 nm  
           Flow rate                          :  1.0 ml/min  
          Temperature                             :   25ºC 
 
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 4.4 min. The peaks observed was sharp and RT also shifted  after fourth min but 
RT was moving towards the zero hence this ratio of mobile phases need to some change 
further for method development.  
 
Chromatographic Conditions – 23 
          Stationary phase               :  Enable C18 column  
Mobile phase                                : Solvent A – 1-heptane sulphonic acid 
        Phosphate buffer pH adjusted  to 3.5(with 
 Orthophosphoric acid) 
                                                              :  Solvent B – Acetonitrile   
           Solvent ratio                              :  73: 27 (A: B)  
           Detection Wavelength              :  223 nm  
           Flow rate                          :  1.0 ml/min  
          Temperature                             :   25ºC 
 
At the above chromatographic conditions saxagliptin and cipfloxacin were eluted 
at  the retention time of 4.4 min and 8.4 min respectively. The peaks observed was sharp 
hence this method has been  selected further for method development.  
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Chromatographic Conditions – 24 
          Stationary phase               : Enable C18 column  
  Mobile phase                              :  Solvent A – 1-heptane sulphonic acid 
        Phosphate buffer pH adjusted  to 3.5(with 
 Orthophosphoric acid) 
                                                              :  Solvent B – Acetonitrile   
           Solvent ratio                              :  72: 28 (A: B)  
           Detection Wavelength              :  223 nm  
           Flow rate                          :  1.0 ml/min  
          Temperature                             :   25ºC 
  
At the above chromatographic conditions saxagliptin and cipfloxacin were eluted 
at the retention time of 4.53 min and 6.65 min respectively. The peaks observed was 
sharp hence this method has been selected further for method development.  
 
TRIAL CHROMATOGRAMS
 
Fig :01 
MP: ACN & MEOH: KH2PO4 Buffer pH 4.0 (Adjusted with OPA) 40:60 
                             (30:20) 
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Fig :02 
MP:ACN: KH2PO4 Buffer pH 4.0(Adjusted with OPA) 30:70 
 
 
Fig :03 
MP:ACN: KH2PO4 Buffer pH 4.0(Adjusted with OPA) 30:70 
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Fig :04 
MP:ACN: KH2PO4 Buffer pH 4.0(Adjusted with OPA) 40:60 
 
Fig :05 
 MP:ACN: KH2PO4 Buffer pH 5.0(Adjusted with OPA) 35:65 
 
Methodology 
 
Dept. of Pharmaceutical Analysis Page 34 
 
 
Fig :06 
MP:ACN: KH2PO4 Buffer pH 3.0(Adjusted with OPA) 35:65 
 
 
Fig :07 
 MP:ACN: KH2PO4 Buffer pH 3.5(Adjusted with OPA) 35:65 
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Fig :08 
 MP:ACN: KH2PO4 Buffer pH 3.5(Adjusted with OPA) 30:70 
 
 
Fig :09 
MP:ACN: KH2PO4 Buffer pH 3.5(Adjusted with OPA) 25:75 
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Fig :10 
MP:ACN: KH2PO4 Buffer pH 3.5(Adjusted with OPA) 30:70 
 
 
Fig :11 
MP:ACN: KH2PO4 Buffer pH 3.5(Adjusted with OPA) 27:73 
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Fig :12 
 MP:ACN: KH2PO4 Buffer with 1-Heptane sulphonic acid pH 
3.5(Adjusted with OPA) 27:73 
 
 
 
 
OPTIMIZATION OF SEPARATION CONDITIONS 
Effect of pH change in phosphate buffer and mobile phase ratio: 
Table 1. Effect of pH and mobile phase ratio 
Drug pH Buffer:ACN Retention time 
(min) 
Observation 
 
Saxagliptin 
5.02 70:30 3.20 Splitting 
5.50 35:65 3.28 Sharp peak 
 
 
 
 
3.03 35:65 2.89 Sharp peak 
3.52 35:65 2.82 Sharp peak 
3.5 30:70 3.2 Sharp peak 
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Effect of Ratio of Mobile phase 
The mobile phase of Acetonitrile: Methanol: Water:Buffer in various ratios,  were 
tried and the chromatograms were recorded at 223 nm with a flow rate of 1ml/min. 
Finally phosphate buffer with 1-Heptane sulphonic acid was selected ( pH  was adjusted 
to 3.5 with ortho phosphoric acid)  as aqueous phase and acetonitrile as organic phase 
then 72:28 v/v  was  an ideal ratio for the estimation of Saxagliptin from human plasma. 
The standard solution was chromatographed for 12 min, using 28% acetonitrile and 
buffer solution in different pH ranging from 5.0,4.0,4.5,3.0 and 3.5 at 223 nm, the mobile 
phase has the flow rate of 1.0 ml/min using Enable C18 column as stationary phase for 
Saxagliptin determination and pH 3.5 was selected as the ideal pH for the separation of 
Saxagliptin. 
Effect of flow Rate: 
 Keeping the mobile phase ratio 28:72 ACN : phosphate buffer with 1-Heptane 
sulphonic acid were used and the chromatograms were recorded at a flow rate of          
1.0 ml/min. At this flow rate, the peaks were sharp with good resolution. So 1.0 ml/min 
was kept constant for the analysis (flow rate 0.9 ml/min 1.1 ml/min, up to 1.3 ml/min 
were also tried, but did not give any satisfactory results). 
Mobile Phase: 
 Prepare a filtered and degassed mixture of ACN and phosphate buffer pH 3.5 
with 1-Heptane sulphonic acid (28:72 v/v ) which was used as a mobile phase. 
Fixed chromatographic conditions: 
Final Method With Plasma 
Chromatographic Conditions –25 
     Stationary phase                : Enable C18 column   
Mobile phase                               :   Solvent A –Phosphate buffer  with 1- 
        heptane sulphonic acid 
    pH adjusted  to 3.5(with 
Orthophosphoric acid) 
                                                              : Solvent B – Acetonitrile   
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        Solvent ratio                               :  72: 28 (A: B)   
        Detection Wavelength              :  223 nm  
        Flow rate                           :  1.0 ml/min  
        Temperature                             :   25ºC 
 
   Saxagliptin was eluted at retention time of 4.49 min and Ciprofloxacin at 6.7 min 
with sharp peaks. So this method has been selected for the further studies. 
Bio analytical method: 
 Stationary phase               :  Enable C18 column  
Mobile phase                             :  Solvent A – 1-heptane sulphonic acid 
         Phosphate buffer pH adjusted  to 3.5(with 
 Orthophosphoric acid) 
                                                              : Solvent B – Acetonitrile   
         Solvent ratio                              :  72: 28 (A: B)   
         Detection Wavelength             :  223 nm  
         Flow rate                          :  1.0 ml/min  
       Temperature                             :   25ºC 
 
Estimation of Saxagliptin: 
 Estimation of Saxagliptin in plasma by RP- HPLC method was carried out by 
standard calibration method. 
Preparation of standard solution: 
  Solution-A ; Weigh 10 mg of Saxaglptin  was  taken in  to separate 10 ml 
standard flask  and dissolved and made up to 10 ml with ACN (A)   
Solution-B : From the stock solution(A) pipette out  1 ml in to another 10 ml 
standard flask then  made up the volume up to 10 ml with water and ACN with the 
ratio of 50:50(B) . 
Solution (C) : From the B solution pipette out 1 ml and made up to the volume in 
10 ml standard flask and made up the volume up to 10n ml with water and ACN 
with the ratio of 50:50 (solution C). 
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 From the C solution prepared the different concentration of solutions such as 0.5 , 
1.0 , 1.5 , 2.0 and 2.5 µg /ml . 
Preparation of internal standard solution: 
 Preparation of ciprofloxacin was same like saxagliptin,  but based on the 
solubility  water was used as solvent for the dilution. The final concentration of 
ciprofloxacin was 50 µg /ml . These ciprofloxacin solution was used as internal standard 
to Bio analytical method development of saxagliptin. 
Validation: 
Calibration curves were plotted using peak area against concentration of 
corresponding standard solutions. Peak areas of the sample chromatograms were 
reordered and the amount of Saxagliptin were calculated from the regression equation. 
Validation is a process of establishing documented evidence, which provides a 
high degree of assurance that a specific activity will consistently produce a desired result 
or product meeting its predetermined specifications and quality characteristics. 
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Significance of Method Validation: 
 The quality of analytical data is a key factor in the success of a drug development 
program. The process of method development and validation has a direct impact on the 
quality of these data. 
 
Analytical validation is a very important feature of any package of information 
submitted to international regulatory agencies in support of new product marketing or 
clinical trials applications. A thorough method development can almost rule out all 
potential problems, at the same time, a thorough validation programmed can address the 
most common ones and provide assurance to the intended purpose (can be used with 
100% confidence). In other words, a thorough validation can fulfil all the technical and 
regulatory objectives. 
 
Analytical characteristics listed below may not be applicable to every test 
procedure or every particular material. It will mostly depend on the purpose for which 
the procedure is required, however, these following aspects of validation should be given 
due importance. 
 
a) Accuracy: 
Accuracy of the method was determined by recovery experiments. The reference 
standards of the respective drug were added to the sample solution at the level of 50%, 
100% and 150%. These were further diluted by procedure as followed in the estimation 
of formulation. The concentrations of the drugs present in the resulting sample solution 
were determined by using assay method.   
 
 
b) Precision: 
The precision of the developed method was determined in terms of intermediate 
precision (intra-day and inter-day). Three  same concentrations were analyzed in five 
independent series during the same day (intra-day precision) and three consecutive days 
(inter-day precision); with each series every sample was injected in triplicate. The %RSD 
values of intra-day and inter-day studies showed that the precision of the method was 
satisfactory. 
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c) Linearity and range: 
From the standard stock solutions, a suitably mixed standard and Internal 
standard solution was prepared. Saxagliptin were found to be linear in the range of 0.5 to 
2.5 µg/ml. The solutions were examined by the assay procedure. The calibration curve 
was plotted using peak area Vs concentration of the standard solution. From the 
calibration curve, the slope and intercept were calculated.  
 
d) Limit of detection (LOD) and Limit of quantification (LOQ): 
         The LOD and LOQ were separately determined and reported, based on the 
calibration curve of standard solution. The residual standard deviation of the regression 
line or the standard deviation of y – intercepts of regression lines may be used to 
calculate LOD and LOQ. LOD = 3.3 × D/S and LOQ = 10 × D/S, where, D is the 
Standard deviation of y – intercepts of regression line and S is the slope of the calibration 
curve. 
 
LOD is the smallest concentration of the analyte that can be detected and gives 
the measurable response (signal to noise ratio of 3). The signal to noise ratio were 
performed by comparing by measured signal of known low concentration of drug. LOQ 
is the smallest concentration of the analyte that can be accurately quantified (signal to 
noise ratio 10). 
 
e) Specificity: 
The specificity of the RP-HPLC method was determined by complete separation 
of Saxagliptin with parameters like retention time(Rt), resolution (Rs) and tailing factor 
(T), peak purity curve and peak purity index. Tailing factor for peaks of Saxagliptin less 
than 2% and resolution was satisfactory. The peaks obtained for Saxagliptin were sharp 
and have clear baseline separation. The peak purity studies were performed to prove that 
the method is specific in nature.  
 
f) Ruggedness: 
It expresses the precision within laboratory variations like different days, 
different analyst, and different equipments. Ruggedness of the method was assessed by 
spiking the standard concentrations of Saxagliptin , 5 times in two different days with 
different analyst.  
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g) Robustness: 
          In order to demonstrate the robustness of the method, the following optimized 
conditions were slightly varied. 
           1)  ± 2% in ratio of acetonitrile in mobile phase, 
           2)  ± 0.2 ml of flow rate, 
           3) ± 0.2 units in the pH of buffer. 
 
The separation factor, retention times and peak symmetry were then calculated. 
The deviation among the results obtained is well within the limits. Hence the method is 
robust. 
 
h) System Suitability Studies: 
The system suitability studies were carried out as specified in USP. These 
parameters include column efficiency, resolution and capacity factor.  
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                                   7. RESULTS AND DISCUSSION 
 
1. HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD  
A Bio-analytical RP-HPLC method was developed for the Saxagliptin. The 
chromatographic conditions were stabilized in order to provide a good performance of the 
assay. The standard and internal standard solutions were prepared and chromatograms were 
recorded. This project proposes a method for the determination of Saxagliptin from human 
plasma by liquid-liquid extraction  method using RP-HPLC.  
Chromatographic separation of standard Saxagliptin: 
        The chromatogram of Saxagliptin was recorded alone and shown in figure (Fig 
13).The standard solution which contains internal standard Ciprofloxacin was injected 
with the developed chromatographic conditions, and the chromatograms were recorded 
and shown in figure (Fig 14). 
 
 
 
          Fig:13 - Chromatogram of standard Saxagliptin 100µg/ml 
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       Fig:14 Chromatogram of  standard Saxagliptin 0.5µg/ml with (IS) 
 
  The retention time of Saxagliptin and internal standard (Ciprofloxacin) was 4.5 and 
7.2 min respectively with percent RSD of less than 2%. The results are shown in table (Table 
no 3). The peak purity study reveals that signal ratios (relative absorbance at different 
wavelengths) were constant across the peak proﬁle of Saxaglptin. The peaks obtained in the 
present study were symmetric, good and no interference was observed between the peak. 
 
Table No 2: Retention time of Saxagliptin and ciprofloxacin (IS) 
 
S. No Method 
Retention time of Drugs (min) 
Saxagliptin 
Internal Standard 
(Ciprofloxacin) 
 
1 
2 
3 
4 
5 
 
 
 
HPLC 
 
4.523 
4.494 
4.572 
4.508 
4.534 
 
6.654 
6.672 
6.592 
6.618 
6.673 
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       The method developed was advantageous than the reported methods by its lesser 
precision values and increased accuracy values. The run time of 10 minutes makes the 
method rapid and economical than the previously reported methods. 
 
Chromatographic separation of Saxagliptin in biological fluid: 
 
 The chromatogram of the blank plasma was recorded at the fixed chromatographic 
conditions and shown in figure (Fig 15).  
 
       
                             Fig: 15- Chromatogram of blank plasma 
 
 
 Various eluting solvents were used for extraction of Sxagliptin in human plasma. 
But, out of all eluting solvents acetonitrile was proved to be good because of its maximum 
percentage recovery. The percentage recoveries were calculated and shown in table (Table 
no 3). The retention time for Saxagliptin and internal standard (Ciprofloxacin) were 4.4 
and 6.8 minutes  as shown in (Fig 14). The peaks were symmetric with straight baseline. 
 
 The extraction method used for the present study was simple and newer than 
previous methods. For present study protein precipitation technique was used  and ACN  
as eluting solvent was selected because of its maximum recovery of drug from plasma and 
it is advantageous. 
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Table no 3: Recovery study of Saxagliptin 
Level Conc. of 
drug 
added 
(µg /ml) 
Amt. of drug recovered from 
plasma (µg/ml) 
% Recovery 
Methanol ACN 
and 
methanol 
mixture 
ACN Methanol ACN and 
methanol  
mixture 
ACN 
I 0.5 0.23 0.34 0.48 46 68 96 
II 1.0 0.64 0.78 0.97 64 78 97 
III 1.5 1.02 1.12 1.47 68 74.6 98 
                                                
METHOD VALIDATION  
 
a) Accuracy and precision:  
 
 At two –levels these accuracy and precision studies were conducted i.e. intra-day 
and inter-day. In this the present developed method, shown the good accuracy and 
precision. Accuracy ranges from 99.4% to 100.5% with the precision 5.82% to 6.94% in 
intra-day method. In inter-day method the accuracy ranges from 99.8% to 100.8%   with 
the precision 6.61% to 7.69%.  Finally the data obtained here, was found to be within 
limits as per ICH guidelines and method was accurate.  
 
Intra-day studies: In this plasma concentration 500-2500 ng/ml were injected six times 
and mean peak area was calculated separately for each concentration and from that 
accuracy and precision percentage RSD values were calculated and shown in table.                                                                         
(Table No 4)     
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Table no 4: Accuracy and precision studies of Saxagliptin(Intraday) 
Sl.no 
Conc. of       
drug (ng/ml) 
Mean peak 
area 
 
Accuracy 
(%) 
RSD 
(%) 
 
 
1 
 
500 16795 100.5 7.52 
2 1000          32564 99.8 6.96 
3 2000 64438 99.4 6.65 
              **Average of six determinations. 
 
Inter-day studies: In this the plasma concentrations of 500-2500 ng/ml were injected into 
HPLC six times in three different days and mean peak areas were calculated and from that 
accuracy and precision  percentage RSD were calculated and shown in table (Table no 5). 
The percentage relative standard deviation of precision for Saxagliptin was less than 15% for 
the bioanalytical study. The results obtained were within limits. 
Acceptance criteria: The percentage RSD value should be less than 15% for bio-
analytical study. 
 
Table no 5:  Accuracy and precision studies of Saxagliptin (Interday) 
Sl.no 
Conc. of       
drug (g/ml) 
Mean peak 
area 
 
Accuracy 
(%) 
RSD 
(%) 
 
1 500 17395 101.07 7.88 
2 1000          33264 99.7 6.39 
3 2000 63438 100.4 7.49 
**Average of six determinations. 
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b) Linearity and range: 
 This method proved to be linear between ng/ml of Saxagliptin in human plasma, 
with a typical calibration curve of correlation equation y = 0.1535x + 0.0274, correlation 
coefficient > 0.999 shown in table (Table no 6) 
 
 
 
Fig: 16 - Calibration curve for Saxagliptin 
            The chromatograms of the plasma calibration standards with concentrations 500, 
1000, 1500, 2000 and 2500 ng/ml were recorded and shown in figures (Fig 17,18,19, 20 
and 21) and their peak areas of both drug and internal standard were noted. The 
calibration curve for Saxagliptin  was plotted as peak response Vs concentration of the 
Saxagliptin  calibration standards in plasma was shown (in Fig : 16). As we were using 
internal standard peak response was calculated for calibration curve. Peak response is the 
ratio of internal standard peak area to drug peak area. The correlation coefficient of 
Saxagliptin  shown was 0.999 which was within limits. This calibration curve plotted was 
linear and showed that the method had adequate sensitivity to the concentration (500 
ng/ml-2500 ng/ml) of the drug. Finally the data obtained, in this was within limits. 
Coefficient of correlation of Saxgliptin  was found to be less than 0.9998. 
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Acceptance criteria: The correlation coefficient should not less than 0.99 
 
             Fig 17 - Chromatogram of  IS and Saxagliptin in human plasma 500ng/ml 
 
 
         Fig :18 - Chromatogram of IS and Saxagliptin in human plasma 1000ng/ml 
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     Fig :19 - Chromatogram of IS and Saxagliptin in human plasma 1500ng/ml 
 
 
      Fig :20 - Chromatogram of  IS and Saxagliptin in human plasma 2000ng/ml 
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       Fig: 21 - Chromatogram of IS and Saxagliptin in human plasma 2500ng/ml 
 
c) Lower Limit of Quantification: 
 
        The LLOQ is the smallest concentration of the analyte, which shows response that 
can be accurately quantified and LLOQ = 10 × D/S, where, D is the standard deviation of 
y – intercepts of regression line and S is the slope of the calibration curve. This signal to 
noise ratio were performed by comparing measured signal of known low concentration of 
drug with those of blank plasma sample. 
 The Lower limit of quantification (LLOQ) for Saxagliptin were separately 
determined and reported, based on the calibration curve for spiked plasma solutions was 
found to be 96.5  ng/ml.  
 
d) Recovery from plasma: 
        A recovery study for Saxaglitpin in plasma using acetonitrile was shown in table 
(Table no 8). With concentrations 500 ng/ml, 1000 ng/ml, 2000 ng/ml of Saxagliptin 
recovery was calculated and showed 100.3%, 99.8%, 100.3% relative recoveries and 
percentage RSD as 8.7%, 8.0% and 7.2% respectively. From the data obtained, it was 
observed that the recovery of drugs in plasma was found to be 9% which is sufficient for 
bio-analytical study. 
Acceptance criteria: For an assay method, mean recovery should be 85-105% ± 2%. 
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Table no 6: Recovery studies of Saxagliptin 
Levels 
Conc. of 
drug added 
(ng/ml) 
 
Amt of drug 
recovered in 
plasma sample 
(ng /ml) 
Percentage 
recovery 
(%) 
% RSD 
 
I 500 500.3 100.3 8.7 
II 1000 998.5 99.8 8.0 
III 2000 2001.1 100.3 7.2 
                           **Average of six determinations. 
e) Ruggedness: 
 
 It expresses the precision within laboratories variations like different days, 
different analyst, and different equipments. Ruggedness of the method was assessed by 
spiking the plasma standard 6 times in two different days with different analyst and the 
standard solutions were analyzed by a different chemist and same instruments on a 
different day had been performed the reports were shown in table (Table no 7). 
          The deviation among the results obtained by two chemists on a different day was 
well within the limits. Hence the method was rugged. 
Acceptance criteria: The percentage RSD should be less than 15%. 
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Table no 7:  Ruggedness studies for Saxagliptin 
 
Drug 
Concentration 
(ng/ml) 
Mean peak area %RSD 
 
 
 
Day I  analyst – I 
 
 
Saxagliptin 500 17395 6.44 
 
 
Day II  analyst – II 
 
Saxagliptin 500 18146 7.78 
                 **Average of six determinations. 
 
f) Specificity: 
 For specificity the peak purity studies were done. Here for Saxagliptin the peak 
purity index was 000 and the peak properties like peak profile were good for both standard 
and the sample. The peak purity and peak profiles for Saxagliptin without plasma and with 
plasma were shown in figures (Fig 22, 23,24 and 25) respectively. By the data obtained in 
this, the present method developed was specific as values were within limits.  
Acceptance criteria: Purity angle should be less than purity threshold i.e.0.99-1.00 
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Fig :22 - Peak profile of standard Saxagliptin 
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Fig: 23 - Peak profile of Saxagliptin in human plasma 
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                                Fig :24 - Peak purity of standard Saxagliptin 
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                      Fig :25 - Peak purity of Saxagliptin in human plasma 
 
Table no 8: Peak parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO Parameters Saxagliptin 
1. Theoretical Plate 6179.9 
2. Tailing Factor 0.910 
3. HETP 40.08 
4. LLOQ 
 
96.5ng/ml. 
 
5. Resolution 3.56 
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g) System suitability:                                                 
            These parameters were shown to be within specified limits. Column 
efficiency (theoretical plates), resolution factor and peak asymmetry factor, HETP, 
tailing factor, LLOQ are the system suitability parameters. These parameters of the 
optimized methods were found satisfactory. The results of the system suitability 
studies in plasma were shown in table (Table no 8). These parameters were shown 
to be within specified limits 
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8. SUMMARY AND CONCLUSION 
 A simple Reverse Phase High Performance Liquid Chromatographic method has 
been developed and subsequently validated for Saxagliptin estimation in human plasma.  
        The separation method was carried out by using a mobile phase consisting of 
Acetonitrile and potassium dihydrogen ortho phosphate pH 3.5 ±0.05 with 1-Heptane 
sulphonic acid in the ratio of 28:72 v/v. The detection was carried out by using PDA 
detector at 223 nm. The column was Enable C18 (250 X 4.6mm 5 µ). The flow rate was 
selected as 1.0 ml/min.  
        The retention time of Saxagliptin was found to be 4.4 min. The asymmetry factor or 
tailing factor of Saxagliptin was found to be 0.910 which indicates symmetrical nature of 
the peak. The number of theoretical plates of Saxagliptin was found to be 6179.9 which 
indicates the efficient performance of the column. These parameters represent the 
specificity of the method. 
       From the linearity studies, specified concentration levels were determined. It was 
observed that Saxagliptin was linear in the range of 50% to 150% for the target 
concentration by RP-HPLC. The linearity range of Saxagliptin 0.5-2.5µg/ml was found 
to obey linearity with a correlation coefficient of 0.9998.  
              The validation of the proposed method was verified by system precision and 
method precision by RP-HPLC. The %RSD of system suitability for Saxagliptin was 
found to be 0.81.  
 The validation of the proposed method was verified by recovery studies. The 
percentage recovery range was found to be satisfied which represent in results. The 
ruggedness study was also performed.  
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CONCLUSION 
 A RP-HPLC method for bio analytical estimation of Saxagliptin was developed 
and validated  from human plasma  as per  ICH Guidelines. 
 Shimadzu Prominance with PDA Detector and Enable C18 (250x4.6mm, 5µ) 
column, injection of 20 µl was injected and eluted with the mobile phase of Acetonitrile 
and potassium dihydrogen phosphate buffer  pH 3.5 with 1-Hetane sulphonic acid  and 
Acetonitrile in the ratio 28:72, which was pumped at a flow rate of 1.0 ml at 223 nm. The 
peak of Saxagliptin and Ciprofloxacin (IS) was found well separated at 4.56 min and 6.7 
min respectively. The developed method was validated for various parameters as per 
ICH guidelines like system suitability, accuracy, precision, linearity, specificity, 
ruggedness, robustness and solution stability. 
 The Bio-analytical method validation of Saxagliptin by RP HPLC was found to 
be satisfactory and could be used for the routine pharmaceutical analysis of Saxagliptin 
from biological matrix. 
 
 
 
Bibliography 
 
Dept. of Pharmaceutical Analysis Page 60 
 
9. BIBLIOGRAPHY 
 
1. Robert Brown D. Introduction of chemical analysis.1st ed. New Delhi: IVY 
Publishing House;  2001.p.145. 
 
2. Garry D Christian. Analytical Chemistry. 4th ed. London:  University of Wellingt                
2001.p.1-4.               
 
3. David Lee, Michael Webb. Pharmaceutical Analysis. 1st ed. Blackwell Publication;    
2003.p.219. 
 
4. Willard HH, Merritt LL, Dean JJA, Frank AS. Instrumental Method of Analysis. 
7th ed. New Delhi: CBS Publishers and Distributors; 1986. p. 1-4. 
 
5. Takeru higuchi, Einar brochmann, Hamffen hanssen. Text book of pharmaceutical 
analysis.1st ed.   New Delhi: CBS publishers and distributors; 2005.p.1-2. 
 
6. Rashmin. An Introduction To Analytical Method Development For Pharmaceutical 
Formulations. 6th ed. 2008.p.83.  
 
7. Sharma B K. Instrumental Methods of Chemical analysis. 18th ed. Meerut: Krishna 
Prakashan Media (P) Ltd; 1999.p.10-30. 
 
8. Johnson J D, Van Buskirk.  Analytical method validation. Journal of  validation 
technology. 1998; Vol 2: 88-105. 
 
9. Shah PV, Midha KK, Dighe S, McGilvery JI,  Skelly P J, Yacobi A, and Pittman 
A. Analytica method validation: Bioavilbility ,Bioequivalence and 
Pharmacokinetic  studies,   Journal of Pharmaceutical Sciences.1992:81:309-312. 
 
10. Shabir GA. Validation of HPLC Chromatography Methods for Pharmaceutical   
Analysis. Understanding the Differences and Similarities Between Validation  
Requirements of FDA, the US Pharmacopeia and the ICH. J Chromatogram  2003;   
987(1-2):57-66.  
 
11. Lindsay S. High Performance Liquid Chromatography. 1st ed. New York: Wiley                
InterScience; 1991. p. 4,27,71 
Bibliography 
 
Dept. of Pharmaceutical Analysis Page 61 
 
 
12. Meyer VR. Practical High Performance Liquid Chromatography. 2nd ed. New 
York: Wiley InterScience; 1994. p. 98-105. 
 
13. Sethi P D. High performance liquid Chromatography. 1st ed. New Delhi: CBS 
publishers   and distributors.1996.p.17-19. 
 
14. Lough WJ, Wainer IW. High Performance Liquid Chromatography: Fundamental   
Principles and Practice. Glasgow (UK): Blackie Academic & Professional; 1995.  
p.  23-8. 
 
15. Turowski  M, Morimoto T, Kimata  K, Monde  H, Ikegami T, Hosoya  K. 
Selectivity of stationary phases in reversed-phase liquid Chromatography based on 
the   dispersion interactions.  Journal of Chromatography. 2001;  A 911; 177-190. 
 
16. Snyder  L R, Kirkland J J. Introduction to modern liquid chromatography. 2nded.                
Newyirk: John Wiley and Sons:1979. 
 
17. Roger A, Schimer, Quantitative analysis in HPLC, Vol 2, 2nd ed. Pg: 307-311. 
 
18. Joachim Ermer, Miller. Method Validation in Pharmaceutical Analysis. 
Weinheim:  Wiley-vch Verlag GmbH & Co; 2005.p.132. 
 
19. ICH: Q2B Analytical Validation-Methodology (November 1996). 
 
20. Joachim Ermer.Validation in pharmaceutical analysis. Part I: An integrated                 
Approach. Journal of Pharmaceutical and Biomedical Analysis.2001;vol 24: 755–
767. 
 
21. Johnson J D, Van Buskirk,Analytical method validation. journal of validation                
technology.1998;vol 2: 88-105. 
 
22. Jenke D R. Chromatographic method validation: A review of current practices and 
procedures. II. Guidelines for primary validation parameters. Journal of                 
Liquid Chromatography. 1996; vol 19: 737-757.  
 
23. Mulholland  M. Ruggedness testing in analytical chemistry. Trends in analytical                 
Chemistry. 1988;vol 7: 383-389. 
Bibliography 
 
Dept. of Pharmaceutical Analysis Page 62 
 
24. Douglas A, Skoog J James, Leary. Principles of instrumental analysis. 7th edt.               
Thomson Publication;2001.p.1-13. 
 
25. Srinivasa Rao.P, Rama chandran.D, Murali.K and Srinivasu.S "Stability indicating 
isocratic reverse phase HPLC method for the estimation of saxagliptin in bulk 
drugs and in its formulation" International journal of pharma sciences 
vol.3,No.5(2013):333-342. 
26. Bhagavanji N.V.M.S "Development and validation of stability indicating liquid 
chromatographic method for the simultaneous estimation of metformin and 
saxagliptin in combined dosage form" VSRD International Journal of Technical & 
Non-Technical Research, Vol. 3 No. 11 November 2012 . 
27. Vaishali V.Karkhanis , Anandhakumari D.Captain "Development and Validation 
of  liquid chromatographic method for Estimation of saxagliptin in tablet dosage 
form " Journal of Research in Chemistry . Jun2013, Vol. 6 Issue 6, p6-6. 1/3p. 
28. Sarat.M, Murali Krishna.P and Rambabu.C "RP-HPLC method for simultaneous 
estimation of Saxagliptin and Pioglitazone in tablets" International research 
journal of pharmacy, 2012. 
29. Munson J W. Modern Methods of Pharmaceutical Analysis, Part-B. New York:              
Marcel   Dekker Inc; 1984.p.109. 
 
30. Sethi P D. Quantitative Analysis of drugs in pharmaceutical formulations. 3rd ed. 
New   Delhi: CBS publishers and distributors;1997. 
 
31. Chung Chow Chan, Lee Y C, Herman Lam, Xue  Ming Zhang.Analytical Method                       
Validation and Instrument performance Verification.p.no. 35-45. 
 
32. Joachim Ermer.Validation in pharmaceutical analysis. Part I, An integrated         
approach.   Journal of Pharmaceutical and Biomedical Analysis.2001;(2) 24: 755–
767. 
 
33. ICH, Q2A, 1994, Validation of Analytical procedure:  Methodology. In Proc.               
Int.   Con. Harmonization, Geneva. 
 
34. ICH: Q2B Analytical Validation Methodology (November 1996). 
Glossary 
 
Dept. of Pharmaceutical Analysis Page 63 
 
 
                                                       10. GLOSSARY  
1. Degassing: The process of removing dissolved gas from the liquid mobile phase before 
or during use. Degassing is done by heating, by vacuum, or by helium purging. 
2. Drift: The change in the baseline value over time, expressed mathematically as the 
slope of the least line squares line fitted to the base line in a specified region 
chromatogram. 
3. Eluent: Mobile phase used to perform a chromatographic separation .The liquid that 
exits through a chromatographic column during a separation. 
4. Equilibration: The process of bringing a chromatographic solvent (solvent, column, 
and interactive surfaces) to a thermally and chemically stable state, usually indicated by 
a drift –free base line. 
5. External Standard: A separate sample that contains known quantities of the same 
compounds that are in unknown samples. External standards are used for quantitation 
by matching the detector response of a component peak to a point on a calibration 
curve for that component. The calibration curve is generated from a separately 
processed standard (or set of standards). 
6. Fronting peak: An asymmetrically shaped chromatographic peak in which the front 
part of the peak (before the apex) contains more area than the rear of the peak. The 
asymmetry factor for fronting peak has value less than one. The opposite of fronting 
peak is a tailing peak  
7. Fused peak: Two or more no baseline-resolved peaks in a chromatogram that share the 
same base line, the same base line start and end points, and the same slope and offset. 
8. Gradient Elution: Also called as solvent programming, a technique for decreasing the 
separation time by increasing the mobile phase strength over time during a 
chromatographic separation. Gradients can be continuous or stepwise. Binary (2-
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solvent), ternary (3-solvent0 and quaternary (4-solvent) gradients are used routinely in 
HPLC. 
9. Integration: The mathematical process of calculating an area such as a 
chromatographic peak that is bounded in a part or in a whole by a curved line. 
10. Isocratic: The condition in which the solvent composition, flow rate, and the 
temperature are constant during a chromatographic run, the condition in which the 
solvent composition is constant during a chromatographic run. 
11. Linearity: The condition in which detector response is directly proportional to the 
concentration or amount of a component over a specified range of component 
concentrations or amounts .A calibration curve is a straight line when the standard 
concentrations are within the linear response range of the detector. In chromatography, 
accurate quantitation requires linearity of the detector response over the range of actual 
sample concentrations or amounts. 
12. Mobile Phase: The fluid (gas or liquid) that carries solutes through a chromatographic 
column. In LC, the liquid that is pumped through the fluid path of the chromatographic 
system and into which the samples are injected.  
13. Plate count: A measure of the observed chromatographic resolution based on its 
equivalency to the number of theoretical plates that would provide the same resolution. 
14. Resolution: The extent to which a chromatographic column separates components 
from each other.  Mathematically defined, resolution is the difference between the peak 
retention time of a selected peak and the peak preceding its multiplied by a constant of 
1.18,then dived by the sum of the peak widths at 50%of peak height. It is used to 
monitor the separation of eluting components and to establish system efficiency. 
15. Retention Time: The time that elapses between the injection of a sample and the 
appearance of the peak maximum of a component in a sample. 
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16. Rt ratio: The Retention Time of a component divided by the retention time of its 
reference peak. 
17. System suitability: An application that applies a set of standard criteria to test if an 
entire chromatographic system and the methodology are working within acceptable 
limits. Empower software bases the system suitability tests on standard laboratory 
calculations, including United States Pharmacopoeia (USP) guidelines and calculations. 
Empower software produces reports showing statistical accuracy and reproducibility of 
the chromatographic system data.  
18. Tailing Factor: A measure of peak symmetry, where a Symmetrical peak has a tailing 
factor of 1.As Tailing increases, peak symmetry increases for System suitability, the 
tailing factor is the width of the peak at 5% height, divided by two times the distance 
from the peak maximum to the leading edge of the peak (where the distance is 
measured at point 5 % of the peak height from the base line). 
19. Capacity factor: A chromatographic parameter that measures retention time of a 
sample molecule relative to the column dead volume.  
20. Acceptance Criteria: Numerical Limits, ranges, or other suitable for acceptance of the 
results of analytical procedures. 
21. Detection Limit: The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample that can be detected, but not necessarily quantitated as an 
exact value. 
22. Drug Product: A finished dosage form, for example, a capsule, tablet, or solution that 
contains a drug substance, but not necessarily, in association with one or more other 
ingredients. 
23. Drug Substance/Active Ingredient: An active ingredient that is intended to furnish 
pharmacological activity or other direct effect the structure or any function of the 
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human body. The active ingredient does not include intermediates used in the synthesis 
of such ingredient. The term includes those components that may undergo chemical 
change in the manufacture of the drug product and be present in the drug product in a 
modified form intended to furnish the specified activity or effect. 
24. Reagent: For analytical procedures, any substance used in a reaction for the purpose of 
detecting, measuring, examining, or analyzing other substances. 
25. Specification: The quality standards (i.e., tests, analytical procedures, and acceptance 
criteria) provided in an approved application to confirm the quality of the drug 
substances, drug products, intermediates, raw materials, reagents, and other 
components including container closure systems, and in-process materials. 
26. Spiking: The addition of a small known amount of a known compound to a standard, 
sample, or placebo, typically for the purpose of confirming the performance of an 
analytical procedure or the calibration of an instrument. 
27. Working Standard: A standard that is qualified against and used instead of the 
reference standard (also known as in-house or secondary standard). 
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Introduction[1-7]
 Analytical techniques
An analytical chemistry helps to find the characteristics of drug components and
related products by checking its quality and quantity measurements.
• High Performance Liquid Chromatography
Most of the drugs in multicomponent dosage forms can be analyzed by HPLC
method because of the several advantages like good separation, rapidity, specificity,
accuracy, precision and ease of automation in this method.
 Analytical method development and validation [8-18]
Analytical method development and validation play an important role in the 
discovery, development, and manufacture of pharmaceutical formulations.
Method development
Validation of chromatographic methods .
 Bio-Analytical method development [19-24]
The procedures that demonstrate that a particular method used for quantitative
measurement of analytes in a given biological matrix, such as blood, plasma, serum,
or urine, is reliable and reproducible for the intended use.
Literature review
 P. Srinivasa Rao et al25 studied Stability indicating isocratic reverse phase HPLC 
method for the estimation of Saxagliptin in bulk drugs and in its formulation 
Separation was achieved with a Eclipse XDB C18, ( 150 mm × 4.6 mm X 5 μm) 
Column and Potassium di-hydrogen orthophosphate buffer with TEA (pH 
adjusted to 3.4 with OPA): Acetonitrile (80:20) v/v as eluent at a flow rate of 1.0 
mL/min. UV detection was carried out at 213 nm. The retention time of 
Saxagliptin was found to be 3.8 minutes.
 Bhagavanji26 reported that, a study on  development and validation of stability 
indicating liquid chromatographic method for the simultaneous estimation of 
Metformin and Saxagliptin in combined dosage form by thermo Hypersil BDS 
C8 (250mmX4.6mmX5μ) column  was used  with mobile phase containing 
water pH 3.0 adjusted with ortho phosphoric acid: methanol in the ratio of (70: 
30, v/v). The flow rate was 1.0 mL/min, column temparature was 30°C and 
effluents were monitored at 241 nm. The retention times of Metformin and 
Saxagliptin were 4.7min and 6.8 min, respectively. 
 Karkhanis Vaishali  et al27 has reported and study on development and 
validation of a liquid chromatographic method for estimation of Saxagliptin 
in tablet dosage form achieved by Hypersil C18 column (250mm X 4.6mm, 
5μm) in isocratic mode, the mobile phase comprises of Acetonitrile: Buffer 
in ratio of 30:70 v/v, buffer was 0.02M Potassium Di-hydrogen Phosphate 
(pH 4.5 adjusted with OPA). The flow rate of mobile phase was 1.0ml/min 
and detection UV wavelength 220nm. The retention time of saxagliptin was 
3.487 min.
 Sarat et al28 has been reported and study on reverse phase HPLC method for 
simultaneous estimation of Saxagliptin and Pioglitazone in tablets. 
Chromatographic seperation achieved isocratically on Inerstil C18 column 
(150mmX 4.6 mmX5μm) using mobile phase of Acetonitrile and Phosphate 
buffer pH 7.0 (60:40 v/v)at a flow rate of 0.8 ml/min with UV wave length 
of 260 nm. Aceclofenac was used as internal standard. The RT of 
Saxagliptin, pioglitazone and aceclofenac was 2.48, 4.45 and 6.34 min 
respectively. 
 Drug Name :  Saxagliptin
 Molecular formulae : C18H25N3O2
 Molecular weight    : 315.41 g/mol
 Chemical structure           :
 Chemical name :   2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)
acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
 Colour and nature :  White to yellow or light brown crystalline   
powder.
• Solubility                       : Sparingly soluble in water ,slightly soluble in                
ethyl acetate and soluble in methanol,ethanol
,isopropyl alcohol, acetonitrile ,acetone and 
PEG-400.
Drug profile
 Dosage Form :  Available as 2.5 mg and 5 mg tablet.
 Index of Refraction :  1.6.
 Boiling Point :  548.7±35.0 °C at 760 mmHg.
 Class : Carboxylic Acids and Derivatives.
 Half life : 2.5 hours.
 pKa (strongest acidic) : 14.74.
 Category : Oral hypoglycemic agent (anti-diabetic drug)         
(DPP-4 inhibitor.)
 Toxicity :  Upper respiratory tract infection, urinary tract          
infection, and headache.
 Route of elimination : Eliminated by both renal and hepatic              
pathways.
Objective of the work
 Importance of analytical chemistry is to gain information about the
qualitative and quantitative composition of substance and chemical species,
that is, to find out what a substance is composed of and exactly how much it
is present.
 Drug analysis plays an important role in the development of drugs, their
manufacture and therapeutic use. Pharmaceutical industries rely up on
quantitative chemical analysis to ensure that the raw material used and the
final product obtained meets the required specification.
 The prime objective of this work is to develop rapid, selective, sensitive and
economical Bio analytical method for saxagliptin in human plasma with an
internal standard by RP-HPLC method
Plan of Work
 The work plan was to develop RP-HPLC method for Bio analytical 
estimation of Saxagliptin.
The plan of work was divided into two phases.
Phase I:
Optimization of chromatographic conditions 
 Selection of wavelength 
 Selection of initial separation conditions  
 Selection of mobile phase (pH, peak modifier, solvent strength, ratio and 
flow rate)
 Nature of the stationary phase
 Selection of separation method and agent
Phase II:
Validation of the method
The developed method were proposed to be validated using the various 
validation parameters such as, 
 Accuracy
 Precision
 Interday
 Intraday
 Repeatability
 Linearity 
 Limit of detection (LOD) 
 Limit of quantification (LOQ)
 Robustness  
 Ruggedness   
 System suitability.
METHODOLOGY
 HPLC METHOD DEVELOPMENT [29-33]
 MATERIALS AND INSTRUMENTS USED
 a) Drug samples:
 Saxagliptin gift sample was procured from Madras 
pharmaceuticals, Chennai. 
 b) Chemicals and Solvents used:
 Water HPLC Grade
 Acetonitrile HPLC grade
 Methanol HPLC grade
 Orthophosphoric acid AR grade
 1-Heptane sulphonic acid
 Tri ethyl amine
 2) Instruments used:
 Shimadzu AY 220 Electronic Weighing Balance
 Eutech pH meter 
 Sonica Ultrasonicator. 
 Millipore membrane filter 
 Shimadzu prominence HPLC
 Pump – Prominence LC-20AT
 Column -Enable C18 (2) 100A, (250 X 4.6m.m x i.d, 5µ)
 Injector - Rheodyne 7725i with 20 μl loop
 Effect of Ratio of Mobile phase
The mobile phase of Acetonitrile: Methanol: Water:Buffer in various ratios, were
tried and the chromatograms were recorded at 223 nm with a flow rate of 1ml/min.
Finally phosphate buffer with 1-Heptane sulphonic acid was selected ( pH was
adjusted to 3.5 with ortho phosphoric acid) as aqueous phase and acetonitrile as
organic phase then 72:28 v/v was an ideal ratio for the estimation of Saxagliptin
from human plasma.
The standard solution was chromatographed for 12 min, using 28% acetonitrile and
buffer solution in different pH ranging from 5.0,4.0,4.5,3.0 and 3.5 at 223 nm, the
mobile phase has the flow rate of 1.0 ml/min using Enable C18 column as stationary
phase for Saxagliptin determination and pH 3.5 was selected as the ideal pH for the
separation of Saxagliptin.
 Effect of flow Rate:
Keeping the mobile phase ratio 28:72 ACN : phosphate buffer with 1-Heptane
sulphonic acid were used and the chromatograms were recorded at a flow rate of
1.0 ml/min. At this flow rate, the peaks were sharp with good resolution. So 1.0
ml/min was kept constant for the analysis (flow rate 0.9 ml/min 1.1 ml/min, up to
1.3 ml/min were also tried, but did not give any satisfactory results).
 Effect of flow Rate:
Keeping the mobile phase ratio 28:72 ACN : phosphate buffer with 1-
Heptane sulphonic acid were used and the chromatograms were recorded at a 
flow rate of          1.0 ml/min. At this flow rate, the peaks were sharp with good 
resolution. So 1.0 ml/min was kept constant for the analysis (flow rate 0.9 
ml/min 1.1 ml/min, up to 1.3 ml/min were also tried, but did not give any 
satisfactory results).
 Mobile Phase:
Prepare a filtered and degassed mixture of ACN and phosphate buffer 
pH 3.5 with 1-Heptane sulphonic acid (28:72 v/v ) which was used as a mobile 
phase.
Materials
MATERIALS AND INSTRUMENTS USED
a) Drug samples:
Saxagliptin gift sample was procured from Madras pharmaceuticals, 
Chennai. 
b) Chemicals and Solvents used:
 Water HPLC Grade
 Acetonitrile HPLC grade
 Methanol HPLC grade
 Orthophosphoric acid AR grade
 1-Heptane sulphonic acid
 Tri ethyl amine
c) Instruments used:
 Shimadzu AY 220 Electronic Weighing Balance
 Eutech pH meter 
 Sonica Ultrasonicator. 
 Millipore membrane filter 
 Shimadzu prominence HPLC
 Pump – Prominence LC-20AT
 Column -Enable C18 (2) 100A, (250 X 4.6m.m x i.d, 5µ)
 Injector - Rheodyne 7725i with 20 μl loop
 Detector - Photo Diode Array Detector 
Chromatographic Conditions – 1
Stationary phase : Enable C18 column 
Mobile phase : Solvent A –Phosphate buffer p H Adjusted                
to 3.5  (with Orthophosphoric  acid) 
: Solvent B – Acetonitrile
Solvent ratio : 73:27 (A: B) 
Detection Wavelength           : 223 nm 
Flow rate : 1.0 ml/min 
Temperature : 25ºC 
At the above chroma tographic conditions saxagliptin was el uted at  the retention 
time of 3.4 min. The peaks observed was sharp but RT  was before 4 min., hence not selected 
further for method development.
Chromatographic Conditions – 2
Stationary phase : Enable C18 column 
Mobile phase :  Solvent A – 1-heptane sulphonic acid
Phosphate buffer pH adjusted  to 3.5(with
Orthophosphoric acid)
: Solvent B – Acetonitrile  
Solvent ratio                             :  73: 27 (A: B) 
Detection Wavelength            :  223 nm 
Flow rate :  1.0 ml/min 
Temperature              :   25ºC
At the above chromatographic conditions saxagliptin was eluted at  the retention 
time of 4.5min. The peaks observed was sharp and RT also shifted  after fourth min hence 
this buffer has been selected further for method development.
Chromatographic Conditions – 3
Stationary phase : Enable C18 column 
Mobile phase :  Solvent A – 1-heptane sulphonic acid
Phosphate buffer pH adjusted  to 3.5(with
Orthophosphoric acid)
: Solvent B – Acetonitrile  
Solvent ratio                             :  72: 28 (A: B) 
Detection Wavelength            :  223 nm 
Flow rate :  1.0 ml/min 
Temperature              :   25ºC
At the above chroma tographic conditions saxagliptin and cipfloxacin were eluted 
at the retention time of 4.53 min and 6.65 min respectively . The peaks observed was sharp 
hence this method has been selected further for method development.
TRAIL CHROMOTOGRAMS
Fig.1 MP:ACN: KH2PO4 Buffer pH 5.0(Adjusted with OPA) 35:65 Fig.2 MP:ACN: KH2PO4 Buffer pH 3.5(Adjusted with OPA) 25:75
with 1-heptane sulphonic acid

Drug pH Buffer:ACN Retention time
(min)
Observation
Saxagliptin
5.02 70:30 3.20 Splitting
5.50 35:65 3.28 Sharp peak
3.03 35:65 2.89 Sharp peak
3.52 35:65 2.82 Sharp peak
3.5 30:70 3.2 Sharp peak
OPTIMIZATION OF SEPARATION CONDITIONS
Effect of pH change in phosphate buffer and mobile phase ratio:
Table 1. Effect of pH and mobile phase ratio
Results and Discussion
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD 
 A Bio-analytical RP-HPLC method was developed for the Saxagliptin. The 
chromatographic conditions were stabilized in order to provide a good 
performance of the assay. The standard and internal standard solutions were 
prepared and chromatograms were recorded. This project proposes a method 
for the determination of Saxagliptin from human plasma by liquid-liquid 
extraction  method using RP-HPLC.
Chromatographic separation of standard Saxagliptin:
 The chromatogram of Saxagliptin was recorded alone and shown in figure 
(Fig 3).The standard solution which contains internal standard 
Ciprofloxacin was injected with the developed chromatographic conditions, 
and the chromatograms were recorded and shown in figure (Fig 4).
Fig:3 - Chromatogram of standard Saxagliptin 100µg/ml
Fig:4 Chromatogram of  standard Saxagliptin 0.5µg/ml with (IS)
The retention time of Saxagliptin and internal standard (Ciprofloxacin) was
4.5 and 7.2 min respectively with percent RSD of less than 2%. The results
are shown in table (Table no 3). The peak purity study reveals that signal
ratios (relative absorbance at different wavelengths) were constant across
the peak proﬁle of Saxaglptin. The peaks obtained in the present study were
symmetric, good and no interference was observed between the peak.
Table No 2: Retention time of Saxagliptin and ciprofloxacin (IS)
S. No Method
Retention time of Drugs (min)
Saxagliptin Internal Standard(Ciprofloxacin)
1
2
3
4
5
HPLC 4.523
4.494
4.572
4.508
4.534
6.654
6.672
6.592
6.618
6.673
The method developed was advantageous than the reported methods by its 
lesser precision values and increased accuracy values. The run time of 10 
minutes makes the method rapid and economical than the previously 
reported methods.
 Chromatographic separation of Saxagliptin in biological fluid:
The chromatogram of the blank plasma was recorded at the fixed 
chromatographic conditions and shown in figure (Fig 5). 
Fig: 5- Chromatogram of blank plasma
 Various eluting solvents were used for extraction of Sxagliptin in human
plasma. But, out of all eluting solvents acetonitrile was proved to be good
because of its maximum percentage recovery. The percentage recoveries
were calculated and shown in table (Table no 3). The retention time for
Saxagliptin and internal standard (Ciprofloxacin) were 4.4 and 6.8 minutes
as shown in (Fig 4). The peaks were symmetric with straight baseline.
The extraction method used for the present study was simple and newer
than previous methods. For present study protein precipitation technique
was used and ACN as eluting solvent was selected because of its
maximum recovery of drug from plasma and it is advantageous.
Table no 3: Recovery study of Saxagliptin
Level Conc. of
drug 
added 
(µg /ml)
Amt. of drug recovered 
from plasma (µg/ml)
% Recovery
Methano
l
ACN 
and 
methanol 
mixture
ACN Methano
l
ACN 
and 
methanol  
mixture
ACN
I 0.5 0.23 0.34 0.48 46 68 96
II 1.0 0.64 0.78 0.97 64 78 97
III 1.5 1.02 1.12 1.47 68 74.6 98
 METHOD VALIDATION
 a) Accuracy and precision:
 At two –levels these accuracy and precision studies were conducted i.e.
intra-day and inter-day. In this the present developed method, shown the
good accuracy and precision. Accuracy ranges from 99.4% to 100.5% with
the precision 5.82% to 6.94% in intra-day method. In inter-day method the
accuracy ranges from 99.8% to 100.8% with the precision 6.61% to
7.69%. Finally the data obtained here, was found to be within limits as per
ICH guidelines and method was accurate.
 Intra-day studies: In this plasma concentration 500-2500 ng/ml were
injected six times and mean peak area was calculated separately for each
concentration and from that accuracy and precision percentage RSD values
were calculated and shown in table.
(Table No 4)
Table no 4: Accuracy and precision studies of Saxagliptin(Intraday)
Sl.no
Conc. of       
drug (ng/ml)
Mean peak
area
Accuracy
(%)
RSD
(%)
1
500 16795 100.5 7.52
2 1000 32564 99.8 6.96
3 2000 64438 99.4 6.65
**Average of six determinations.
Inter-day studies: In this the plasma concentrations of 500-2500 ng/ml were injected 
into HPLC six times in three different days and mean peak areas were calculated and 
from that accuracy and precision  percentage RSD were calculated and shown in table 
(Table no 5). The percentage relative standard deviation of precision for Saxagliptin 
was less than 15% for the bioanalytical study. The results obtained were within limits.
Acceptance criteria: The percentage RSD value should be less than 15% for bio-
analytical study.
Sl.no Conc. of       drug (g/ml)
Mean peak
area
Accuracy
(%)
RSD
(%)
1 500 17395 101.07 7.88
2 1000 33264 99.7 6.39
3 2000 63438 100.4 7.49
Table no 5:  Accuracy and precision studies of Saxagliptin (Interday)
b) Linearity and range:
This method proved to be linear between ng/ml of Saxagliptin in
human plasma, with a typical calibration curve of correlation equation y =
0.1535x + 0.0274, correlation coefficient > 0.999 shown in table (Table no 6)
Fig: 6 - Calibration curve for Saxagliptin
 The chromatograms of the plasma calibration standards with concentrations
500, 1000, 1500, 2000 and 2500 ng/ml were recorded and their peak areas
of both drug and internal standard were noted. The calibration curve for
Saxagliptin was plotted as peak response Vs concentration of the
Saxagliptin calibration standards in plasma was shown (in Fig : 6). As we
were using internal standard peak response was calculated for calibration
curve. Peak response is the ratio of internal standard peak area to drug peak
area. The correlation coefficient of Saxagliptin shown was 0.999 which was
within limits. This calibration curve plotted was linear and showed that the
method had adequate sensitivity to the concentration (500 ng/ml-2500
ng/ml) of the drug. Finally the data obtained, in this was within limits.
Coefficient of correlation of Saxgliptin was found to be less than 0.9998.
 Acceptance criteria: The correlation coefficient should not less than 0.99
Fig 7 - Chromatogram of  IS and Saxagliptin in human plasma 500ng/ml
Fig 8 - Chromatogram of  IS and Saxagliptin in human plasma 2000ng/ml
 c) Lower Limit of Quantification:
The LLOQ is the smallest concentration of the analyte, which shows
response that can be accurately quantified and LLOQ = 10 × D/S, where, D
is the standard deviation of y – intercepts of regression line and S is the
slope of the calibration curve. This signal to noise ratio were performed by
comparing measured signal of known low concentration of drug with those
of blank plasma sample.
The Lower limit of quantification (LLOQ) for Saxagliptin were separately
determined and reported, based on the calibration curve for spiked plasma
solutions was found to be 96.5 ng/ml.
 d) Recovery from plasma:
 A recovery study for Saxaglitpin in plasma using acetonitrile was
shown in table (Table no 8). With concentrations 500 ng/ml, 1000 ng/ml,
2000 ng/ml of Saxagliptin recovery was calculated and showed 100.3%,
99.8%, 100.3% relative recoveries and percentage RSD as 8.7%, 8.0% and
7.2% respectively. From the data obtained, it was observed that the recovery
of drugs in plasma was found to be 9% which is sufficient for bio-analytical
study.
 Acceptance criteria: For an assay method, mean recovery should be 85-
105% ± 2%.
 Table no 6: Recovery studies of Saxagliptin
Levels
Conc. of drug 
added
(ng/ml)
Amt of drug 
recovered in 
plasma sample
(ng /ml)
Percentage 
recovery
(%)
% RSD
I 500 500.3 100.3 8.7
II 1000 998.5 99.8 8.0
III 2000 2001.1 100.3 7.2
e) Ruggedness:
It expresses the precision within laboratories variations like different days, 
different analyst, and different equipments. Ruggedness of the method was 
assessed by spiking the plasma standard 6 times in two different days with different 
analyst and the standard solutions were analyzed by a different chemist and same 
instruments on a different day had been performed the reports were shown in table 
(Table no 7).
The deviation among the results obtained by two chemists on a different day
was well within the limits. Hence the method was rugged.
Acceptance criteria: The percentage RSD should be less than 15%.
Table no 7:  Ruggedness studies for Saxagliptin
Drug
Concentration 
(ng/ml)
Mean peak area %RSD
Day I  analyst – I
Saxagliptin 500 17395 6.44
Day II  analyst – II
Saxagliptin 500 18146 7.78
**Average of six determinations.
f) Specificity:
For specificity the peak purity studies were done. Here for Saxagliptin the peak purity 
index was 000 and the peak properties like peak profile were good for both standard and the 
sample. The peak purity and peak profiles for Saxagliptin without plasma. By the data obtained 
in this, the present method developed was specific as values were within limits.
Acceptance criteria: Purity angle should be less than purity threshold i.e.0.99-1.00
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Fig :9 - Peak profile of standard Saxagliptin
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Fig: 10 - Peak profile of Saxagliptin in human plasma
4.15 4.20 4.25 4.30 4.35 4.40 4.45 4.50 4.55 4.60 4.65 4.70 4.75 4.80 4.85 min
0.000
0.025
0.050
0.075
0.100
0.125
0.150
0.175
0.200
0.225
0.250
0.275
0.0
25.0
50.0
75.0
100.0
125.0
150.0
175.0
200.0
225.0
250.0
275.0
300.0
mAU
Peak
Zero Line
Purity  Curv e
Fig :11 - Peak purity of standard Saxagliptin
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Fig :12 - Peak purity of Saxagliptin in human plasma
Table no 8: Peak parameters
S.NO Parameters Saxagliptin
1. Theoretical Plate 6179.9
2. Tailing Factor 0.910
3. HETP 40.08
4. LLOQ 96.5ng/ml.
5. Resolution 3.56
g) System suitability:
These parameters were shown to be within specified limits.
Column efficiency (theoretical plates), resolution factor and peak
asymmetry factor, HETP, tailing factor, LLOQ are the system suitability
parameters. These parameters of the optimized methods were found
satisfactory. The results of the system suitability studies in plasma were
shown in table (Table no 8). These parameters were shown to be within
specified limits
Summary & Conclusion
 A simple Reverse Phase High Performance Liquid Chromatographic
method has been developed and subsequently validated for Saxagliptin
estimation in human plasma.
 The separation method was carried out by using a mobile phase
consisting of Acetonitrile and potassium dihydrogen ortho phosphate pH 3.5
±0.05 with 1-Heptane sulphonic acid in the ratio of 28:72 v/v. The detection
was carried out by using PDA detector at 223 nm. The column was Enable
C18 (250 X 4.6mm 5 µ). The flow rate was selected as 1.0 ml/min.
 The retention time of Saxagliptin was found to be 4.4 min. The
asymmetry factor or tailing factor of Saxagliptin was found to be 0.910
which indicates symmetrical nature of the peak. The number of theoretical
plates of Saxagliptin was found to be 6179.9 which indicates the efficient
performance of the column. These parameters represent the specificity of
the method.
 From the linearity studies, specified concentration levels were
determined. It was observed that Saxagliptin was linear in the range of
50% to 150% for the target concentration by RP-HPLC. The linearity
range of Saxagliptin 0.5-2.5µg/ml was found to obey linearity with a
correlation coefficient of 0.9998.
 The validation of the proposed method was verified by system precision
and method precision by RP-HPLC. The %RSD of system suitability for
Saxagliptin was found to be 0.81.
 The validation of the proposed method was verified by recovery studies.
The percentage recovery range was found to be satisfied which represent
in results. The ruggedness study was also performed.
Conclusion
 A RP-HPLC method for bio analytical estimation of Saxagliptin was
developed and validated from human plasma as per ICH Guidelines.
 Shimadzu Prominance with PDA Detector and Enable C18 (250x4.6mm,
5µ) column, injection of 20 µl was injected and eluted with the mobile
phase of Acetonitrile and potassium dihydrogen phosphate buffer pH 3.5
with 1-Hetane sulphonic acid and Acetonitrile in the ratio 28:72, which was
pumped at a flow rate of 1.0 ml at 223 nm. The peak of Saxagliptin and
Ciprofloxacin (IS) was found well separated at 4.56 min and 6.7 min
respectively. The developed method was validated for various parameters as
per ICH guidelines like system suitability, accuracy, precision, linearity,
specificity, ruggedness, robustness and solution stability.
 The Bio-analytical method validation of Saxagliptin by RP HPLC was
found to be satisfactory and could be used for the routine pharmaceutical
analysis of Saxagliptin from biological matrix.
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